소아 간질 환자에서 oxcarbazepine의 효용성과 안전성
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신혜경 | - |
dc.contributor.author | 이윤 | - |
dc.contributor.author | 이지연 | - |
dc.contributor.author | 최욱선 | - |
dc.contributor.author | 은소희 | - |
dc.contributor.author | 은백린 | - |
dc.contributor.author | 홍영숙 | - |
dc.contributor.author | 이주원 | - |
dc.date.accessioned | 2021-09-09T13:56:17Z | - |
dc.date.available | 2021-09-09T13:56:17Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2008 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/124746 | - |
dc.description.abstract | Purpose:Oxcabarzepine (OXC), newly recommended antiepileptic drug, has been prescribed for patients with partial seizures and generalized tonic clonic seizures in Korea from 1999. There are limited reports about an efficacy of OXC therapy in epileptic children in Korea. This study evaluated the efficacy and safety of OXC in the light of our experience. Methods:The patients, who had visited the pediatric neurology clinic of Korea University Guro Hospital from January 2001 to December 2006, were included. The data of 144 patients who were administrated OXC as monotherapy or polytherapy, was summarized retrospectively and we evaluated the efficacy and safety of OXC. Results:After 6 months of OXC therapy, 77 patients (53.5%, n=144) achieved seizure freedom, 48 patients (33.3%) experienced >50% improvement. After 12 months of OXC therapy, cessation of seizure was observed in 88 patients (61.1%, n=133), and 27 patients (18.8%) manifested an improvement. Monotherapy group showed superior efficacy to polytherapy one. The frequent side effects of OXC were drowsiness (20.1%), headache (12.5%), dizziness (9.7%) and rash (8.3%). They did not related to patient's age or sex, and dosage of OXC. Twenty four patients (16.7%) experienced hyponatremia, but which were neither symptomatic nor significant one. Conclusion:The efficacy and safety of OXC in our patients were excellent and had less significant side effects than established international one. We expect this report contributes toward OXC therapy in epileptic children. (Korean J Pediatr 2008;51:162-169) | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.publisher | 대한소아청소년과학회 | - |
dc.title | 소아 간질 환자에서 oxcarbazepine의 효용성과 안전성 | - |
dc.title.alternative | Efficacy and safety of oxcarbazepine in epileptic children | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 은백린 | - |
dc.identifier.bibliographicCitation | Clinical and Experimental Pediatrics, v.51, no.2, pp.162 - 169 | - |
dc.relation.isPartOf | Clinical and Experimental Pediatrics | - |
dc.citation.title | Clinical and Experimental Pediatrics | - |
dc.citation.volume | 51 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 162 | - |
dc.citation.endPage | 169 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001222793 | - |
dc.description.journalClass | 3 | - |
dc.subject.keywordAuthor | Oxcarbazepine | - |
dc.subject.keywordAuthor | Efficacy | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Child | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.